Last updated: February 22, 2026
What is the drug associated with NDC 65162-0804?
The NDC 65162-0804 corresponds to Ubrogepant (brand name: Ubrelvy), an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for acute treatment of migraine in adults.
Market Overview
Ubrogepant entered the migraine treatment market in 2019, experiencing competitive effects from existing therapies like triptans and neuromodulators. Its distinctive feature is non-vasoconstrictive action, suitable for patients with cardiovascular risks.
Market Size and Growth
- Global migraine medication market (2021): Valued at approximately $4.7 billion.
- Forecast (2026): Projected to reach $6.8 billion, with a CAGR of 7.4% (ResearchAndMarkets, 2022).
Competitive Landscape
- Major competitors: Sumatriptan, Rizatriptan, and lasmiditan.
- Market share (2022): Ubrelvy held an estimated 12% in the acute migraine treatment segment.
- Pricing strategies: Premium pricing relative to generics, targeting chronic migraine sufferers.
Pricing Data for NDC 65162-0804
Current Wholesale Acquisition Cost (WAC)
- Average WAC: Approximately $48 per tablet (per 50 mg dose).
Average Sales Price (ASP)
- Estimated ASP: Around $52 per tablet, factoring in insurance and pharmacy markup.
Insurance Reimbursement
- Average negotiated price: Approximately $45–$50 per unit for commercial payers.
- Medicaid/Medicare: Reimbursement rates vary; Medicaid rebates significantly reduce costs.
Dosing Regimen
- Typically, a 50 mg or 100 mg tablet, administered as needed for acute migraine episodes, with a maximum of 2 doses per day.
Price Projection Assumptions (Next 5 Years)
| Year |
Estimated WAC |
Assumptions |
| 2023 |
$48–$50 |
Stable entry price; minor adjustments for inflation |
| 2024 |
$50–$52 |
Potential price increase due to inflation or formulary negotiations |
| 2025 |
$52–$55 |
Introduction of generic competitors or biosimilars may exert downward pressure |
| 2026 |
$50–$53 |
Price stabilization; potential market share gains or losses |
Factors Influencing Price Dynamics
- Generic entry: If biosimilars or generics enter, prices could decline by 15–20%.
- Market expansion: Increased provider prescribing and insurance coverage may support sustained or increased prices.
- Regulatory changes: Price controls or incentives for biosimilar uptake could influence pricing.
Regulatory and Market Access Outlook
- FDA status: Approved since 2019 for acute migraine.
- Market access: Expanding insurance coverage and value-based contracts may stabilize prices.
- Potential for formulary inclusion: Increased formulary acceptance could support higher reimbursement rates.
Key Market Risks
- Patent expiry: Patent for ubrogepant set to expire around 2030, opening door for generics.
- Competitive drugs: Lasmiditan (Reyvow) and new CGRP antagonists may erode Ubrogepant's market share.
- Pricing pressures: Cost containment efforts by payers could reduce revenue potential.
Summary of Market Outlook
Ubrogepant remains a niche but growing segment of migraine therapies. Its premium pricing persists due to targeted patient needs and moderate market penetration. The arrival of generics post-2030 and new entrants may pressure prices downward. Short-term, prices are expected to hover around current levels, with slight increases driven by inflation and market expansion.
Key Takeaways
- Current wholesale price: ~$48–$50 per tablet.
- Market share: 12% in acute migraine segment (2022).
- Growth prospects: Steady, supported by increased insurance coverage and prescription volume.
- Price trajectory: Stable through 2024, potential decline post-2025 with generic entry.
- Risks: Patent expiration, market competition, regulatory influences.
FAQs
Q1: When is the expected patent expiration for ubrogepant?
A1: Around 2030, which could facilitate generic competition.
Q2: How does ubrogepant price compare to other migraine treatments?
A2: It is priced higher than generics like triptans, but comparable to or slightly higher than other CGRP antagonists.
Q3: What factors could cause price increases or decreases?
A3: Increased insurance coverage or market expansion may sustain prices; generic entry and regulatory price controls may reduce them.
Q4: Can new formulations impact market prices?
A4: Yes, improved delivery options or combination therapies could shift pricing patterns.
Q5: How do payer negotiations influence the actual price paid?
A5: Negotiated reimbursement often reduces the list price by 10–15% for commercial payers and more for Medicaid and Medicare.
References
- ResearchAndMarkets (2022). Global migraine medication market report.
- FDA (2019). Ubrogepant approval announcement.
- IQVIA (2022). National outpatient prescription data.
- Medicare.gov, Medicaid.gov. Reimbursement policies and rates.
[1] Centers for Medicare & Medicaid Services. (2022). Reimbursement rate summaries.
